Skip to main content
. 2019 Aug 1;1(4):278–285. doi: 10.1016/j.jhepr.2019.07.006

Fig. 3.

Fig. 3

Time- and dose-dependent Myrcludex B binding to NTCP. (A) Fluorescence intensity of Myrcludex B-FITC on U2OS-HA-hNTCP cells measured by confocal microscopy directly or 24 h after treatment (scale bar 10 μm). (B) Taurocholate uptake assay in U2OS-HA-hNTCP cells 0 h, 1 h, and 24 h after Myrcludex B treatment. (C) Fluorescence intensity of concentration range of Myrcludex B-FITC on U2OS-HA-hNTCP cells measured by Clariostar. (D) Taurocholate uptake assay in U2OS-HA-hNTCP cells pre-incubated with the indicated concentrations of Myrcludex B for 10 min. (B-D) n = 8 from 2 or 3 independent experiments. All data are represented as mean ± SD. FITC, fluorescein isothiocyanate; HA, hemagglutinin; NTCP, sodium taurocholate co-transporting polypeptide.